{"entity":{"id":"surgimab","kind":"company","name":"Surgimab","aka":["SurgiMab SAS"],"tldr":"Surgimab is a French company whose fluorescent antibody SGM-101 lights up carcinoembryonic antigen so surgeons can see colorectal and pancreatic tumours in the operating theatre.","summary":"Surgimab develops SGM-101, a chimeric antibody against carcinoembryonic antigen (CEA) conjugated to a near-infrared fluorophore for fluorescence-guided surgery. Injected a few days before the operation, it marks CEA-expressing tumour deposits so surgeons can find peritoneal metastases, small liver lesions and positive margins. Phase 2 studies in colorectal and pancreatic cancer showed changed surgical plans in a substantial share of patients, and a phase 3 trial in colorectal cancer has completed.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.surgimab.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["sgm-101"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Montpellier","country":"FR","companyType":"biotech","website":"https://www.surgimab.com/","investors":[],"funding":[]},"route":"/companies/surgimab/","neighbours":{"drug":[{"id":"sgm-101","kind":"drug","name":"SGM-101","route":"/drugs/sgm-101/"}]}}